Valuation: Tengion, Inc.

Market Cap 110K 98.06K 91.49K 83.1K 157K 10.62M 158K 1.1M 430K 5.4M 412K 403K 17.36M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.96M 4.63M 4.2M 7.92M 537M 7.98M 55.61M 21.73M 273M 20.84M 20.39M 878M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%+16.67% - - 402
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-1.16%+23.36%+79.34% 58.81B
+0.17%-1.16%+3.59%+34.55% 48.45B
+0.50%-1.77%+331.24%+702.20% 42.84B
-0.72%-4.04%+25.90%+29.94% 42.79B
+0.34%-0.34%+5.66%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.37%-9.42%-14.35% 24.05B
Average -0.27%-0.25%+52.65%+123.79% 43.81B
Weighted average by Cap. +0.48%-0.54%+55.51%+130.20%

Financials

2012 2013
Net sales - -
Net income -16.93M -15.13M -14.11M -12.82M -24.14M -1.64B -24.32M -170M -66.25M -833M -63.55M -62.18M -2.68B -18.93M -16.91M -15.78M -14.33M -26.99M -1.83B -27.19M -190M -74.07M -931M -71.06M -69.52M -2.99B
Net Debt 3.73M 3.34M 3.11M 2.83M 5.32M 361M 5.36M 37.39M 14.61M 184M 14.01M 13.71M 590M 5.44M 4.86M 4.54M 4.12M 7.76M 526M 7.82M 54.51M 21.3M 268M 20.43M 19.99M 861M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-